Abstract

FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows

Author(s): Brunner Scott

Issue: May/Jun 2021 - Volume 25, Number 3

View All Articles in Issue

Page(s): 206-209

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2021 Pg. 206-209	FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Author(s): Brunner Scott
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Nov/Dec 2020 Pg. 444	PreScription: The NASEM cBHT Report, Part 1 Author(s): Allen Loyd V Jr
Nov/Dec 2020 Pg. 446-448	NASEM Report on Compounded Topical Pain Creams Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Jan/Feb 2001 Pg. 52-54	Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Author(s): Ford Gina, Garcia Lea
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Sep/Oct 2020 Pg. 356	Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Jan/Feb 2021 Pg. 4	PreScription: The NASEM cBHT Report, Part 2 Author(s): Allen Loyd V Jr
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Nov/Dec 2020 Pg. 466-470	Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1 Author(s): DeRosa Angela
Jan/Feb 2021 Pg. 14-17	Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 2 Author(s): DeRosa Angela
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Mar/Apr 2014 Pg. 117-118	IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities Author(s): Miller David G
Jul/Aug 2004 Pg. 313-319	Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J